700 related articles for article (PubMed ID: 17157792)
1. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies.
Chin K; DeVries S; Fridlyand J; Spellman PT; Roydasgupta R; Kuo WL; Lapuk A; Neve RM; Qian Z; Ryder T; Chen F; Feiler H; Tokuyasu T; Kingsley C; Dairkee S; Meng Z; Chew K; Pinkel D; Jain A; Ljung BM; Esserman L; Albertson DG; Waldman FM; Gray JW
Cancer Cell; 2006 Dec; 10(6):529-41. PubMed ID: 17157792
[TBL] [Abstract][Full Text] [Related]
2. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series.
Desmedt C; Piette F; Loi S; Wang Y; Lallemand F; Haibe-Kains B; Viale G; Delorenzi M; Zhang Y; d'Assignies MS; Bergh J; Lidereau R; Ellis P; Harris AL; Klijn JG; Foekens JA; Cardoso F; Piccart MJ; Buyse M; Sotiriou C;
Clin Cancer Res; 2007 Jun; 13(11):3207-14. PubMed ID: 17545524
[TBL] [Abstract][Full Text] [Related]
3. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups.
Curtis C; Shah SP; Chin SF; Turashvili G; Rueda OM; Dunning MJ; Speed D; Lynch AG; Samarajiwa S; Yuan Y; Gräf S; Ha G; Haffari G; Bashashati A; Russell R; McKinney S; ; Langerød A; Green A; Provenzano E; Wishart G; Pinder S; Watson P; Markowetz F; Murphy L; Ellis I; Purushotham A; Børresen-Dale AL; Brenton JD; Tavaré S; Caldas C; Aparicio S
Nature; 2012 Apr; 486(7403):346-52. PubMed ID: 22522925
[TBL] [Abstract][Full Text] [Related]
4. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.
Hatzis C; Pusztai L; Valero V; Booser DJ; Esserman L; Lluch A; Vidaurre T; Holmes F; Souchon E; Wang H; Martin M; Cotrina J; Gomez H; Hubbard R; Chacón JI; Ferrer-Lozano J; Dyer R; Buxton M; Gong Y; Wu Y; Ibrahim N; Andreopoulou E; Ueno NT; Hunt K; Yang W; Nazario A; DeMichele A; O'Shaughnessy J; Hortobagyi GN; Symmans WF
JAMA; 2011 May; 305(18):1873-81. PubMed ID: 21558518
[TBL] [Abstract][Full Text] [Related]
5. Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen.
Loi S; Haibe-Kains B; Desmedt C; Wirapati P; Lallemand F; Tutt AM; Gillet C; Ellis P; Ryder K; Reid JF; Daidone MG; Pierotti MA; Berns EM; Jansen MP; Foekens JA; Delorenzi M; Bontempi G; Piccart MJ; Sotiriou C
BMC Genomics; 2008 May; 9():239. PubMed ID: 18498629
[TBL] [Abstract][Full Text] [Related]
6. The humoral immune system has a key prognostic impact in node-negative breast cancer.
Schmidt M; Böhm D; von Törne C; Steiner E; Puhl A; Pilch H; Lehr HA; Hengstler JG; Kölbl H; Gehrmann M
Cancer Res; 2008 Jul; 68(13):5405-13. PubMed ID: 18593943
[TBL] [Abstract][Full Text] [Related]
7. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade.
Loi S; Haibe-Kains B; Desmedt C; Lallemand F; Tutt AM; Gillet C; Ellis P; Harris A; Bergh J; Foekens JA; Klijn JG; Larsimont D; Buyse M; Bontempi G; Delorenzi M; Piccart MJ; Sotiriou C
J Clin Oncol; 2007 Apr; 25(10):1239-46. PubMed ID: 17401012
[TBL] [Abstract][Full Text] [Related]
8. Genes that mediate breast cancer metastasis to the brain.
Bos PD; Zhang XH; Nadal C; Shu W; Gomis RR; Nguyen DX; Minn AJ; van de Vijver MJ; Gerald WL; Foekens JA; Massagué J
Nature; 2009 Jun; 459(7249):1005-9. PubMed ID: 19421193
[TBL] [Abstract][Full Text] [Related]
9. The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy.
Zhang Y; Sieuwerts AM; McGreevy M; Casey G; Cufer T; Paradiso A; Harbeck N; Span PN; Hicks DG; Crowe J; Tubbs RR; Budd GT; Lyons J; Sweep FC; Schmitt M; Schittulli F; Golouh R; Talantov D; Wang Y; Foekens JA
Breast Cancer Res Treat; 2009 Jul; 116(2):303-9. PubMed ID: 18821012
[TBL] [Abstract][Full Text] [Related]
10. A gene expression signature identifies two prognostic subgroups of basal breast cancer.
Sabatier R; Finetti P; Cervera N; Lambaudie E; Esterni B; Mamessier E; Tallet A; Chabannon C; Extra JM; Jacquemier J; Viens P; Birnbaum D; Bertucci F
Breast Cancer Res Treat; 2011 Apr; 126(2):407-20. PubMed ID: 20490655
[TBL] [Abstract][Full Text] [Related]
11. Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization.
Kao KJ; Chang KM; Hsu HC; Huang AT
BMC Cancer; 2011 Apr; 11():143. PubMed ID: 21501481
[TBL] [Abstract][Full Text] [Related]
12. Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer.
Li Y; Zou L; Li Q; Haibe-Kains B; Tian R; Li Y; Desmedt C; Sotiriou C; Szallasi Z; Iglehart JD; Richardson AL; Wang ZC
Nat Med; 2010 Feb; 16(2):214-8. PubMed ID: 20098429
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive molecular portraits of human breast tumours.
Cancer Genome Atlas Network
Nature; 2012 Oct; 490(7418):61-70. PubMed ID: 23000897
[TBL] [Abstract][Full Text] [Related]
14. Deconstructing the molecular portraits of breast cancer.
Prat A; Perou CM
Mol Oncol; 2011 Feb; 5(1):5-23. PubMed ID: 21147047
[TBL] [Abstract][Full Text] [Related]
15. A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer.
Chanrion M; Negre V; Fontaine H; Salvetat N; Bibeau F; Mac Grogan G; Mauriac L; Katsaros D; Molina F; Theillet C; Darbon JM
Clin Cancer Res; 2008 Mar; 14(6):1744-52. PubMed ID: 18347175
[TBL] [Abstract][Full Text] [Related]
16. Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival.
Weigman VJ; Chao HH; Shabalin AA; He X; Parker JS; Nordgard SH; Grushko T; Huo D; Nwachukwu C; Nobel A; Kristensen VN; Børresen-Dale AL; Olopade OI; Perou CM
Breast Cancer Res Treat; 2012 Jun; 133(3):865-80. PubMed ID: 22048815
[TBL] [Abstract][Full Text] [Related]
17. High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer.
Staaf J; Jönsson G; Ringnér M; Vallon-Christersson J; Grabau D; Arason A; Gunnarsson H; Agnarsson BA; Malmström PO; Johannsson OT; Loman N; Barkardottir RB; Borg A
Breast Cancer Res; 2010; 12(3):R25. PubMed ID: 20459607
[TBL] [Abstract][Full Text] [Related]
18. High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer.
Chin SF; Teschendorff AE; Marioni JC; Wang Y; Barbosa-Morais NL; Thorne NP; Costa JL; Pinder SE; van de Wiel MA; Green AR; Ellis IO; Porter PL; Tavaré S; Brenton JD; Ylstra B; Caldas C
Genome Biol; 2007; 8(10):R215. PubMed ID: 17925008
[TBL] [Abstract][Full Text] [Related]
19. Supervised risk predictor of breast cancer based on intrinsic subtypes.
Parker JS; Mullins M; Cheang MC; Leung S; Voduc D; Vickery T; Davies S; Fauron C; He X; Hu Z; Quackenbush JF; Stijleman IJ; Palazzo J; Marron JS; Nobel AB; Mardis E; Nielsen TO; Ellis MJ; Perou CM; Bernard PS
J Clin Oncol; 2009 Mar; 27(8):1160-7. PubMed ID: 19204204
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
